Preclinical News and Research

RSS

New drug DSM265 shows potential to cure, prevent malaria

Researchers at UT Southwestern Medical Center and in Australia have shown that a drug currently in testing shows potential to cure malaria in a single dose and offers promise as a preventive treatment as well.

16 Jul 2015

UK investment lacking for pneumonia research

UK investment in pneumonia research is lacking when compared to spending on influenza and tuberculosis, according to a new study by the University of Southampton and University College London.

15 Jul 2015

Oxford University performs second phase of experimental Ebola vaccine trial

Oxford University doctors and scientists are performing the second phase of clinical studies of an experimental Ebola vaccine regimen. The study is part of the EBOVAC2 project, a collaborative programme involving the University of Oxford, French Institute of Health and Medical Research as project coordinator, London School of Hygiene & Tropical Medicine, Le Centre Muraz, Inserm Transfert and the Janssen Pharmaceutical Companies of Johnson & Johnson.

15 Jul 2015

IU researcher plays role in recent FDA approval of Neupogen drug to treat people exposed to radiation

An Indiana University Melvin and Bren Simon Cancer Center researcher played a role in the recent Food and Drug Administration approval of a drug to treat people exposed to potentially lethal doses of radiation.

15 Jul 2015

MR Solutions unveils preclinical, cryogen-free MRI systems at ISMRM 2015 and SNMMI 2015

Delegates visiting MR Solutions’ new exhibition stand at ISMRM 2015 and SNMMI 2015, in June 2015, were thrilled to see the company’s 3T, 4.7T and 7T MRI cryogen-free magnet technology for preclinical imaging.

From MR Solutions 15 Jul 2015

New analysis explores importance of medical imaging in drug development, understanding pathological physiology

The use of small animal models in basic and preclinical research is now an integral part of developing and testing new pharmaceutical drugs prior to commercialisation.

14 Jul 2015

MPI applications: an interview with Tobias Knopp, University Hospital Hamburg

Up to now, we've seen a lot of improvements made, but now we're almost at the point of focusing on the application of MPI and proving what the real benefits of this technology are, which is very exciting...

From Bruker BioSpin Group 12 Jul 2015

Turnstone announces ongoing enrollment of Marabex clinical trial

Turnstone Biologics Inc., a FACIT portfolio company, has announced the ongoing enrollment of the Marabex clinical trial assessing the safety and immune responses in patients with advanced or metastatic, MAGE-A3-expressing solid tumours.

12 Jul 2015

UTHealth scientist receives $1.9 million from NIH to develop non-antibiotic treatment for C. diff infections

Charles Darkoh, Ph.D., a researcher at The University of Texas Health Science Center at Houston School of Public Health, was recently awarded a five-year, $1.9 million R01 grant by the National Institutes of Health to develop a non-antibiotic treatment for Clostridium difficile (C. diff) infections.

10 Jul 2015

Recently-developed drug holds great promise for children with acute lymphoblastic leukaemia

A new Australian study shows that a recently-developed drug, already used safely in adult leukaemia clinical trials, holds great promise for some children with an aggressive form of cancer known as acute lymphoblastic leukaemia (ALL).

10 Jul 2015

Isis Innovation, Ludwig Cancer Research announce launch of new cancer immunotherapy spinout

Isis Innovation, the University of Oxford's technology commercialisation company, and Ludwig Cancer Research are proud to announce the launch of a new spinout company, iOx Therapeutics. iOx Therapeutics will develop a novel cancer immunotherapy discovered through a collaboration between Ludwig Cancer Research and Professor Vincenzo Cerundolo, the director of the MRC Human Immunology Unit within the University of Oxford's Weatherall Institute of Molecular Medicine.

9 Jul 2015

UC San Diego, GSK collaborate to treat leukemia by eliminating cancer stem cells

Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center are working with GSK on a bench-to-bedside project to treat leukemia and other diseases by eliminating cancer stem cells. The collaboration is part of GSK's Discovery Partnerships with Academia (DPAc) program, where academic partners become core members of drug-hunting teams.

9 Jul 2015

News study shows pregnancy complications tied to future cardiovascular disease risk

According to a new study, women can accurately recall key pregnancy-related information at least 4 years later that could have important implications for their future risk of developing cardiovascular disease (CVD).

8 Jul 2015

Abide Therapeutics begins Phase 1a study of ABX-1431 investigational endocannabinoid system modulator

Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of enrollment and dosing of the first subject in a Phase 1a clinical study of ABX-1431, a first-in-class, investigational endocannabinoid system modulator.

7 Jul 2015

Tests reveal that FY26 cancer drug is 49 times more potent than Cisplatin drug

Tests have shown that a new cancer drug, FY26, is 49 times more potent than the clinically used treatment Cisplatin.

7 Jul 2015

City of Hope researchers to use patients' own modified T cells to treat advanced brain tumors

Already pioneers in the use of immunotherapy, City of Hope researchers are now testing the bold approach to cancer treatment against one of medicine's biggest challenges: brain cancer. This month, they will launch a clinical trial using patients' own modified T cells to fight advanced brain tumors.

7 Jul 2015

NIH-sponsored clinical trial evaluates new investigational vaccine against West Nile Virus infection

A clinical trial of a new investigational vaccine designed to protect against West Nile Virus infection will be sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

7 Jul 2015

Using nanocarriers and microbubbles in drug delivery for treating thrombotic disease

Future Science Group today announced the publication of a new article in Future Science OA, covering the use of nanocarriers and microbubbles in drug delivery for thrombotic disease.

7 Jul 2015

European Nanomedicine Characterization Lab aims to bring safe, efficient nano-therapeutics to patients

Empa, the Swiss Federal Laboratories for Materials Science and Technology, is part of the European Nanomedicine Characterization Laboratory, a European project funded by the EU framework program «Horizon 2020.

2 Jul 2015

Avexxin concludes second phase I/IIA study in patients suffering from mild-to-moderate psoriasis

Avexxin AS, a therapeutic company focusing on the discovery and development of novel small molecule therapeutics for patients suffering from chronic inflammatory conditions, announces the completion of a second phase I/IIa study showing Proof-of-Concept in man.

2 Jul 2015

Preclinical News and Research

New drug DSM265 shows potential to cure, prevent malaria

UK investment lacking for pneumonia research

Oxford University performs second phase of experimental Ebola vaccine trial

IU researcher plays role in recent FDA approval of Neupogen drug to treat people exposed to radiation

MR Solutions unveils preclinical, cryogen-free MRI systems at ISMRM 2015 and SNMMI 2015

New analysis explores importance of medical imaging in drug development, understanding pathological physiology

MPI applications: an interview with Tobias Knopp, University Hospital Hamburg

Turnstone announces ongoing enrollment of Marabex clinical trial

UTHealth scientist receives $1.9 million from NIH to develop non-antibiotic treatment for C. diff infections

Recently-developed drug holds great promise for children with acute lymphoblastic leukaemia

Isis Innovation, Ludwig Cancer Research announce launch of new cancer immunotherapy spinout

UC San Diego, GSK collaborate to treat leukemia by eliminating cancer stem cells

News study shows pregnancy complications tied to future cardiovascular disease risk

Abide Therapeutics begins Phase 1a study of ABX-1431 investigational endocannabinoid system modulator

Tests reveal that FY26 cancer drug is 49 times more potent than Cisplatin drug

City of Hope researchers to use patients' own modified T cells to treat advanced brain tumors

NIH-sponsored clinical trial evaluates new investigational vaccine against West Nile Virus infection

Using nanocarriers and microbubbles in drug delivery for treating thrombotic disease

European Nanomedicine Characterization Lab aims to bring safe, efficient nano-therapeutics to patients

Avexxin concludes second phase I/IIA study in patients suffering from mild-to-moderate psoriasis

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics